COVID-19 plus flu test allows patients to collect sample at home

Dec 07, 2020 - 03:13 PM
FDA product update

The Food and Drug Administration Friday authorized the first prescription diagnostic test for both COVID-19 and influenza A and B that allows patients to collect a sample at home and ship it to a laboratory for analysis.

The Quest Diagnostics test received emergency use authorization for use by individuals with a suspected respiratory viral infection consistent with COVID-19 when their health care provider deems home collection appropriate.

“With just one swab or sample, combination tests that are authorized for use with home-collected samples can be used to get answers to Americans faster, in the comfort and relative safety of their home, which allows patients to continue to quarantine while awaiting results,” said FDA Commissioner Stephen Hahn, M.D.

Related News Articles

Headline
CDC says COVID-19 cases growing or likely growing in 45 states 
COVID-19 infections are growing or likely growing in 45 states and not changing in five states, according to the latest data from the Centers for Disease…
Headline
CDC, HHS recommend RSV, seasonal flu vaccines
The Centers for Disease Control and Prevention and the Department of Health and Human Services adopted Aug. 4 the Advisory Committee on Immunization Practices…
Headline
Pediatric flu deaths reach 266 for 2024-2025 season
Five pediatric flu deaths were reported to the Centers for Disease Control and Prevention last week, pushing the total to 266 for the 2024-2025 flu season,…
Headline
HHS adopts recommendation to remove thimerosal from all flu vaccines
The Department of Health and Human Services July 23 announced it is recommending the removal of thimerosal from all U.S. flu vaccines. The announcement follows…
Headline
FDA announces recall of cefazolin by Sandoz for mislabeling
The Food and Drug Administration July 15 announced a recall by Sandoz on certain lots of cefazolin, due to the lots being mislabeled as penicillin G potassium…
Headline
COVID-19 vaccination approved for older adults and high-risk, younger children
 The Food and Drug Administration July 10 approved Moderna’s Spikevax COVID-19 vaccine for children under 12 with at least one underlying condition that…